Profile

Research

Publications

Team

Alumni

Priya Srinivas, PhD

Scientist E-II

+91-471-2529495

priyasrinivas@rgcb.res.in

Dr-Priya
  • Profile

    • Ph.D, Biochemistry (Regional Cancer Centre, University of Kerala)
    • M.Sc, Biochemistry (Mahatma Gandhi University, Kerala)
    • 2009 July – 2010 July, Visiting Scientist, Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
    • August 2000 – till date, Scientist, Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala – 695 014
    • 2016: Selected for Indian Council of Medical Research (ICMR) Prem Nath Wahi Award, 2013.
    • 2016: NCI's Cancer Prevention Fellowship Program held from July 6th, 2016 to August 5th, 2016 at National Cancer Institute, National Institutes of Health, USA.
    • 2013: Member - Biotech S&T Delegation to Spain (20-24/05/2013) for encouraging partnerships and business led R&D&I collaborative projects between India and Spain, jointly by the Department of Biotechnology, Ministry of Science and Technology, India and the Centre for the Development of Industrial Technology, Ministry of Economy and Competitiveness, Spain.
    • 2009: DBT overseas Associateship (Visiting Scientist, Mayo Clinic, Rochester, Minnesota, USA).
    • 2008: AACR-NCI International Investigator Opportunity Grants in recognition of the need to globalize cancer research and to equalize the exchange of scientific knowledge – presented at AACR meeting at Washington DC
    • 2008: DBT overseas fellowship 2008-09
    • 2004: DST Young Scientist Project (Fast Track Scheme)
    • 1997: Senior Research Fellowship (UGC), India
    • 1995: Junior Research Fellowship (UGC), India
    • 1994: 1st rank in M.Sc Biochemistry, Mahatma Gandhi University, Kerala
    • 2005: Life Member, Society for Biotechnologists, India
    • 2006: Life Member, Biotech Research Society of India
    • 2007: Member: Third World Organization for Women in Science
    • 2008-cont: Active Member, American Association for Cancer Research
    • 2009: Member, The European Association for Cancer Research
    • 2013: Life Member, Indian Association for Cancer Research
    • 2017-18: Executive Committee Member, Indian Association for Cancer Research

    Ongoing

    • Revathy N
    • Satheesh Kumar S
    • Arathi Rajan
    • Geetu Rose Varghese
    • Neetha R L

    Completed

    • Thasni K A
    • Rakesh S Nair
    • Veena Somasundaram
    • Sreelatha KH
    • Reshma RS

    Journals

    • Oncogene, Nature Publishing Group
    • Apoptosis, Springer Publishers
    • Brain Research Bulletin, Elsevier Publishers
    • BMC Cancer
    • Cancer Biomarkers, IOS press
    • Molecular Oncology
    • Dr.Priya Srinivas, Dr. M.R. Prathapachandra Kurup, Easwaran Potti Manoj, and Rakesh Sathish Nair. ["Synthesis and anticancer activity of a novel Cu (II) coordination complex" (Indian Patent application filed March 2007. No. IP05525/RB/SGM/sm)]
  • Research

    The global scenario rates Breast Cancer to be the second most prevalent cancer among women, after skin cancer, representing 16% of all the female cancers. Nevertheless, an effective chemotherapeutic agent either for the prevention or cure of this deadly disease has not been identified yet. Of the germline mutations in BRCA1 identified, 50% cases contribute to hereditary breast cancers and approximately 80% of the cases result in hereditary breast and ovarian cancers. Decreased BRCA1 expression due to hypermethylation of the BRCA1 promoter or the loss of BRCA1 allele has been reported in 30 - 40% of sporadic breast cancers as well. Thus BRCA1 plays a cardinal role in the breast cancer development. Triple negative breast (TNB) tumors, which accounts for 15% of the breast cancers, frequently harbor homologous recombination (HR) defects due to BRCA1 dysfunction. Even though the evidences suggest that platinated agents are best suited chemotherapeutic targets in TNB's with HR deficiency, there is a safety concern regarding the side effects of these intercalators due to their non targeted behavior and the increased cases of relapse after the chemotherapy. The DNA repair defect characteristic of BRCA1 deficient cells confers sensitivity to PARP inhibitors as monotherapeutic targets or with platinated drugs as combination agents. One of the main focuses of our lab is in identification of novel molecules to target BRCA1 deficient tumors.

    Our lab also focuses on analyzing the role of BRCA1 in human mammary stem cell fate using in vitro systems and has found that BRCA1 defect increases the stem-like behavior in the normal human mammary cells, thus BRCA1 is a regulator of mammary stem cell fate. It has been reported that the mouse mammary tumors induced by the conditional deletion of BRCA1 results in the eventual drug resistance after their initial response to doxorubicin or docetaxel therapy and this phenomenon is due to the existence of cellular sub-compartment within the tumor which possess a subset of cells with stem-like behavior. These cells if isolated and characterized may provide a useful model for drug development for improvement of the existing treatment regimes.

    Prostate is the most consistently reported site for cancer susceptibility in male carriers of BRCA1 mutation. The rate of increase in the incidence of prostate cancer but isn't paralleled by the exploration of their etiology or their risk. Hence their optimal clinical management regimes are not yet defined. We try to analyze the effect of certain drugs in the prostate cancer cells with regard to BRCA1/2 presence and absence.

    Recent studies indicate that the tumor progression is characterized by local accumulation of extracellular matrix components and connective tissue cells surrounding the tumor cluster, a phenomenon termed as the tumor-stroma interaction. The presence of Cancer Associated Fibroblasts (CAFs), one of the major tumor stroma components, seem to be a necessary requirement for the growth and dissemination of several tumor cells since they secrete proteins that may stimulate adhesion, motility and escape from the local growth control as well as angiogenesis. Our research interest encompasses involvement of tumor microenvironment particularly CAF, on tumor invasion and metastasis. By studying the effect of CAFs on cancer cells, the main aim is to understand the possible role of the stromal components in the development and the invasive nature of breast cancer.

    Extramural funds:

    Sl no Grant agency Project title Status
    1 BRNS Effects of Cancer Associated Fibroblasts (CAFs) on BRCA1+/- breast cancer cells; Relation to aggressiveness (PI) Ongoing
    2 KSCSTE ß HCG and BRCA1 in Gestational Trophoblastic Disease (PI) Ongoing
    3 ICMR Can BRCA1 mediated DNA repair be mediated by Estrogen Receptor – Alpha? (PI) Ongoing
    4 BRNS Studies on Regulation of Cell Growth by BRCA1/2 in Prostate Cancer Cells: Influence of Certain Selected Quinones (PI) Completed
    5 DBT Molecular evidence for potential use of plumbagin in brca1 blocked/ mutated cancers (I) Completed
    6 ICMR Effects of phytoestrogens (emodin & genistein) on BRCA1 blocked ovarian cancer cells (PI). Completed
    7 DST Potential role of plumbagin as an anticancer agent in brca1 blocked ovarian cancer cells: comparison with standard chemotherapeutic agents (PI). Completed
    8 KSCSTE Selective gene expression by plumbagin in BRCA1 blocked ovarian cancer cells: An analysis by subtractive hybridization (PI). Completed
    9 DAE Mechanisms of anticancer activity of emodin/aloe emodin: effects on cell growth, angiogenesis and metastasis in human colon cancer cells (Co-I). Completed
    10 DBT Studies on matrix metalloproteinsase (MMP) gene transcription by nitric oxide: mechanism of MMP gene induction in human colon cancer cells (Co-I). Completed
  • Publications

    Papers Published

    1. Sarada Achyutuni, Revathy Nadhan, Satheesh Kumar Sengodan and Priya Srinivas. The Prodigious Network of Chromosome 17 miRNAs Regulating Cancer Genes that Influence the Hallmarks of Cancer. Seminars in Oncology, 10 November 2017, https://doi.org/10.1053/j.seminoncol.2017.11.001.
    2. Satheesh Kumar Sengodan, Arathi Rajan, Sreelatha Krishnakumar Hemalatha, Revathy Nadhan, Abdul Jaleel and Priya Srinivas. Proteomic profiling of β-hCG induced spheres in BRCA1 defective triple negative breast cancer cells. Journal of Proteome Research, Publication Date (Web): October 13, 2017; DOI: 10.1021/acs.jproteome.7b00562.
    3. Satheesh Kumar Sengodan, Revathy Nadhan, Rakesh Sathish Nair, Sreelatha K Hemalatha, Veena Somasundaram, Reshma R S, Arathi Rajan, Neetha R L, Geetu Rose Varghese, Ratheeshkumar Thankappan, Jerald Mahesh Kumar, Arkadiusz Chil, Thapasimuthu Vijayamma Anilkumar, Priya Srinivas. BRCA1 regulation on β-hCG: A mechanism for tumorigenicity in BRCA1 defective breast cancer.Oncogenesis , 2017 Sep 4;6(9):e376. doi: 10.1038/oncsis.2017.75.
    4. Revathy Nadhan, Jayashree V Vaman, Nirmala C, Satheesh Kumar Sengodan, Sreelatha Krishnakumar Hemalatha, Arathi Rajan, Geetu Rose Varghese, Neetha R L, Amritha Krishna B V, Ratheeshkumar Thankappan, Priya Srinivas. Insights into dovetailing GTD and Cancers. Crit Rev Oncol Hematol 114, 77-90. 2017 Apr 07.
    5. Rakesh Sathish Nair, Easwaran Potti Manoj, Ratheeshkumar Thankappan, Sivakumar Krishnankutty Chandrika, M.R. Prathapachandra Kurup and Priya Srinivas. Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer. Molecular Carcinogenesis. 2017 Jan 4. doi: 10.1002/mc.22610.
    6. V. Somasundaram, R. Nadhan, K.H. S, S. Kumar Sengodan, and P. Srinivas. Nitric oxide and reactive oxygen species: Clues to target oxidative damage repair defective breast cancers. Crit Rev Oncol Hematol. 101:184-192 (2016).
    7. V. Somasundaram, S.K. Hemalatha, K. Pal, S. Sinha, A.S. Nair, D. Mukhopadhyay, and P. Srinivas. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells. BMC cancer. 16:336 (2016).
    8. S.R. R, H.S. K, V. Somasundaram, S.K. S, R. Nadhan, R.S. Nair, and P. Srinivas. Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells. Pharmacol Res. 105:134-145 (2016).
    9. R.S. Nair, J.M. Kumar, J. Jose, V. Somasundaram, S.K. Hemalatha, S.K. Sengodan, R. Nadhan, T.V. Anilkumar, and P. Srinivas. Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB). Sci Rep. 6:26631 (2016).
    10. P.M. Aswathy, P.S. Jairani, S.K. Raghavan, J. Verghese, S. Gopala, P. Srinivas, and P.S. Mathuranath. Progranulin mutation analysis: Identification of one novel mutation in exon 12 associated with frontotemporal dementia. Neurobiol Aging. 39:218 e211-213 (2016).
    11. V. Vijayakurup, C. Spatafora, C. Tringali, P.C. Jayakrishnan, P. Srinivas, and S. Gopala. Phenethyl caffeate benzoxanthene lignan is a derivative of caffeic acid phenethyl ester that induces bystander autophagy in WiDr cells. Mol Biol Rep. 41:85-94 (2014).
    12. P. Srinivas, D. Wink, K.P. Mohanakumar, and M.R. Pillai. The legacy of nitric oxide: impact on disease biology. Nitric Oxide. 43:1-2 (2014).
    13. R.S. Nair, M. Kuriakose, V. Somasundaram, V. Shenoi, M.R. Kurup, and P. Srinivas. The molecular response of vanadium complexes of nicotinoyl hydrazone in cervical cancers--a possible interference with HPV oncogenic markers. Life Sci. 116:90-97 (2014).
    14. S. Sinha, K. Pal, A. Elkhanany, S. Dutta, Y. Cao, G. Mondal, S. Iyer, V. Somasundaram, F.J. Couch, V. Shridhar, R. Bhattacharya, D. Mukhopadhyay, and P. Srinivas. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 132:1201-1212 (2013).
    15. A.T. K, R. T, R. G, C.S. K, R.S. Nair, S. G, A. Banerji, V. Somasundaram, and P. Srinivas. Structure activity relationship of plumbagin in BRCA1 related cancer cells. Mol Carcinog. 52:392-403 (2013).
    16. D. Vira, S.K. Basak, M.S. Veena, M.B. Wang, R.K. Batra, and E.S. Srivatsan. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer metastasis reviews. 31:733-751 (2012).
    17. V. Vijayakurup, S. Carmela, D. Carmelo, T. Corrado, P. Srinivas, and S. Gopala. Phenethyl caffeate benzo[kl]xanthene lignan with DNA interacting properties induces DNA damage and apoptosis in colon cancer cells. Life Sci. 91:1336-1344 (2012).
    18. P. Suboj, S. Babykutty, D.R. Valiyaparambil Gopi, R.S. Nair, P. Srinivas, and S. Gopala. Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. Eur J Pharm Sci. 45:581-591 (2012).
    19. P. Suboj, S. Babykutty, P. Srinivas, and S. Gopala. Aloe emodin induces G2/M cell cycle arrest and apoptosis via activation of caspase-6 in human colon cancer cells. Pharmacology. 89:91-98 (2012).
    20. V. Somasundaram and P. Srinivas. Insights into the targeted elimination of BRCA1-defective cancer stem cells. Med Res Rev. 32:948-967 (2012).
    21. S. Babykutty, P. Suboj, P. Srinivas, A.S. Nair, K. Chandramohan, and S. Gopala. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis. 29:471-492 (2012).
    22. S. Babykutty, P.P. S, N.R. J, M.A. Kumar, M.S. Nair, P. Srinivas, and S. Gopala. Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-kappaB in colon cancer cells. Mol Carcinog. 51:475-490 (2012).
    23. P. Srinivas, C.R. Patra, S. Bhattacharya, and D. Mukhopadhyay. Cytotoxicity of naphthoquinones and their capacity to generate reactive oxygen species is quenched when conjugated with gold nanoparticles. Int J Nanomedicine. 6:2113-2122 (2011).
    24. K.A. Thasni, G. Rojini, S.N. Rakesh, T. Ratheeshkumar, M.S. Babu, G. Srinivas, A. Banerji, and P. Srinivas. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur J Pharmacol. 588:158-164 (2008).
    25. K.A. Thasni, S. Rakesh, G. Rojini, T. Ratheeshkumar, G. Srinivas, and S. Priya. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. Ann Oncol. 19:696-705 (2008).
    26. S. Nair, R.R. Nair, P. Srinivas, G. Srinivas, and M.R. Pillai. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog. 47:22-33 (2008).
    27. S. Babykutty, J. Padikkala, P.P. Sathiadevan, V. Vijayakurup, T.K. Azis, P. Srinivas, and S. Gopala. Apoptosis induction of Centella asiatica on human breast cancer cells. Afr J Tradit Complement Altern Med. 6:9-16 (2008).
    28. G. Srinivas, S. Babykutty, P.P. Sathiadevan, and P. Srinivas. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 27:591-608 (2007).
    29. P. Srinivas, G. Gopinath, A. Banerji, A. Dinakar, and G. Srinivas. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog. 40:201-211 (2004).
    30. G. Srinivas, L.A. Annab, G. Gopinath, A. Banerji, and P. Srinivas. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol Carcinog. 39:15-25 (2004).
    31. G. Srinivas, R.J. Anto, P. Srinivas, S. Vidhyalakshmi, V.P. Senan, and D. Karunagaran. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol. 473:117-125 (2003).
    32. P. Srinivas, M. Madhavan, I. Ahamed, E. Abraham, N.R. Vijayalakshmy, and P. Balaram. Nm23H1 and p53 proteins are differentially correlated to metastasis in breast carcinoma. Neoplasma. 49:225-230 (2002).
    33. P. Srinivas, E. Abraham, I. Ahamed, M. Madhavan, N.R. Vijayalakshmi, M.K. Nair, and P. Balaram. Apoptotic index: use in predicting recurrence in breast cancer patients. J Exp Clin Cancer Res. 21:233-238 (2002).
    34. M. Madhavan, P. Srinivas, E. Abraham, I. Ahmed, N.R. Vijayalekshmi, and P. Balaram. Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism. Pathol Oncol Res. 8:125-128 (2002).
    35. M. Madhavan, P. Srinivas, E. Abraham, I. Ahmed, A. Mathew, N.R. Vijayalekshmi, and P. Balaram. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol. 14:423-427 (2001).

    Editorial

    1. Priya Srinivas, David Wink, Kochupurackal P. Mohanakumar, M. Radhakrishna Pillai. The Legacy of Nitric Oxide: Impact on Disease Biology, Nitric Oxide Biology and Chemistry, Nitric Oxide. 2014 Dec 1;43:1-2. doi: 10.1016/j.niox.2014.09.005.

    Book Chapter

    1. Reshma R S, Revathy Nadhan and Priya Srinivas. Plumbagin and Prostate Cancer Therapy. In the book "Complementary and Alternative Medicines in Prostate Cancer: A Comprehensive Approach", ISBN 9781498729871 - CAT# K26099, by CRC Press, December 6, 2016.
    2. Satheesh Kumar S, Sreelatha K H,, Revathy Nadhan, and Priya Srinivas. Role of BRCA1 in Breast Cancer Metastasis. Charpter 1, In the book "Gynecologic Cancers - Basic Sciences, Clinical and Therapeutic Perspectives", ISBN 978-953-51-4278-2, InTech, Europe, March 2nd, 2016.
    1. Priya Srinivas, Shankar Sashidhar, Glycoprotein levels in cateractous Lens, Abstract, Proceedings Kerala Science Congress, 1995.
    2. Priya Srinivas, Iqhal Ahmed, Elizabeth Abraham, K.S.Nair, P.P.Nair, V.G.Chellam, N.R.Vijayalekshmy, M.K.Nair & Prabha Balaram. NM23H1and C-ERB B2 in Breast Cancers. National Conference on Molecular Diagnostics,Trivandrum, Kerala, June 27-29,1998.
    3. Priya Srinivas, Elizabeth Abraham, K.S.Nair, Iqbal Ahamed, Chellam.P.p.Nair, N.R.Vijayalakshmy, M.K.Nair and Prabha Balaram. IS NM23H1 Gene Related to Apoptosis in Breast Cancer. InternationalSymposium on Apoptosis, October 30-31, 1998.
    4. Priya Srinivas, Elizabeth Abraham, Iqbal Ahmed, Chellam V G, N R Vijayalakshmi, M K Nair and Prabha Balaram. P53 and PCNA expression as indicators of Metastasis in nfiltrating Ductal Carcinomas. Abstract, p183-85, Proceedings of 11th Kerala Science Congress, Kasaragod, Feb 27- Mar 1, 1999.
    5. Priya Srinivas, Prabha Balaram, Paul Murugan, Elizabeth Abraham, Iqbal Ahmed, N.R. Vijayalakshmi and M.K. Nair. C-erbB2 oncogene expression and its correlation with tumour suppressor genes, proliferation and other epidemiologic parameters in node negative and node positive breast cancers. XV Asia Pacific Cancer Conference, Madras, Dec. 12th – 15th, 1999.
    6. Priya Srinivas, Elizabeth Abraham, Sukumaran N, Iqbal Ahamed, Balaraman Nair M, Prabha Balaram. Prognostic value of antimetastatic protein nm23H1 and tumor suppressor protein p53 in Breast cancers. Proceedings of 13th Kerala Science Congress, Jan, 2001.
    7. Maya Madhavan, Priya Srinivas, Iqbal Ahmed, Elizabeth Abraham, N.R. Vijayalakshmi and Prabha Balaram. Cadherins as markers of nodal metastasis in breast cancers.19th annual convention of Indian Association for Cancer Research, Thrissur, Jan 21-23, 2000.
    8. Priya Srinivas, P Murugan, E Abraham, N.R. Vijayalakshmi, P Balaram. BRCA1gene alterations in patients with breast cancer in Kerala: A preliminary report. Proceedings of 14th Kerala Science Congress, Jan 29-31, 2002.
    9. Maya Madhavan, Prabha Balaram and Priya Srinivas. E-cadherin probably linked to cell proliferation in Breast Cancer. Proceedings of 14th Kerala Science Congress, Jan 29-31, 2002.
    10. Priya Srinivas, Maya Madhavan, N. R. Vijayalakshmi, Prabha Balaram. Cyclin D1 and c-erbB-2 expression in breast cancer. IABMS, Pondicherry, 2002.
    11. Priya Srinivas, Prabha Balaram, Sangeetha Mohan, Maya Madhavan, Iqbal Ahmed, Elizabeth Abraham and N.R. Vijayalekshmi. Alterations of p53 and BRCA1genes in breast carcinoma. Indian Association for Cancer Research 22nd Annual Convention and International Symposium on Recent Advances in Cancer Causes and Control; Jan 10-12, 2003.
    12. Maya Madhavan, Abraham E, Ahmed I, Vijayalakshmi N.R, Srinivas P and Balaram P. Beta Catenin mutatiopns in relation to histology, stage and metastatic potential of breast cancer - A preliminary study. Indian Association for Cancer Research 22nd Annual Convention and International Symposium on Recent Advances in Cancer Causes and Control; Jan 10-12, 2003.
    13. Srinivas G, Ruby john Anto, Priya Srinivas, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through induction of poly (ADP ribose) polymerase cleavage and activation of caspases. Abstract p 129, 22nd Annual meeting of Indian Association of Cancer Research, Thiruvananthapuram, January 10-12, 2003.
    14. Priya Srinivas and Gopal Srinivas. Plumbagin inhibits nuclear translocation of ERa in BRCA1 blocked ER overexpressing BG-1 ovarian cancer cells. Indian Science Congress, Kolkatta, Jan, 2004.
    15. Rojini.G, Thasni.K.A, Ratheeshkumar.T, Srinivas G and Priya Srinivas. Anticancer activity of genistein on BRCA1 blocked estrogen receptor (ER) positive BG1 ovarian cancer cells. International Symposium on translational research ,apoptosis and cancer, 18th to 21st December 2005.
    16. Thansi KA, Srinivas G and Priya Srinivas. Plumbagin induces RAB 18 in the absence of BRCA1 in ovarian cancer cells. International Symposium on translational research, apoptosis and cancer, 18th to 21st December 2005.
    17. Priya Srinivas, Thansi KA and Rakesh.S A study of effects of Cisplatin and Doxorubicin in comparison to Plumbagin in BRCA1 blocked human ovarian cancer cells. SL.27 International Symposium on translational research, apoptosis and cancer, 18th to 21st December 2005.
    18. Sreekala Nair, Priya Srinivas, Reghuram Nair, and M Radhakrishna Pillai. Invitro characterization of plumbagin as a radiosensitizer for Cervical cancer cells. Pp 95, International Symposium on translational research ,apoptosis and cancer, 18th to 21st December 2005 (Second best poster award)
    19. Suboj Babykutty, Jose Padikkala, Priya Srinivas, Gopal Srinivas. Growth inhibitory and apoptosis inducing effect of methanolic extract of centella asiatica (L) in MCF-7 cells. Pp 60, International Symposium on translational research, apoptosis and cancer, 18th to 21st December 2005.
    20. Thasni K.A, Rakesh S, Rojini G, Ratheeshkumar T, Srinivas G, Asoke Banerji, Priya Srinivas. Plumbagin a magic bullet in BRCA1 mutated cancer therapy Abstract published in proceedings of national seminar conducted by societies for biotechnologists India December 2006.
    21. Thasni K A, Shivakumar K.C, Priya Srinivas. Mechanism of action of plumbagin in BRCA1 blocked ovarian cancer cells: an analysis by suppression subtractive hybridization (SSH) and micro array published in the proceedings of 19th kerala science congress held at Kannur, Kerala January 2007.
    22. Thasni K A, Rojini G, Srinivas G, Asoke Banerji, Priya Srinivas .Molecular mechanism of action of plumbagin in BRCA1 blocked ovarian cancer cell line by suppression subtractive hybridization and micro array Proceedings of the 5th International Symposium on Targeted Anticancer Therapies 2007, held at Amsterdam, The Netherlands on March 8-10, 2007.
    23. Priya Srinivas, Thasni K A, Rakesh S Nair, Rojini G, Ratheeshkumar T, AsokeBanerji, Srinivas G, Targeted anticancer therapy for BRCA1 blocked estrogen receptor positive ovarian cancers. Proceedings of the 5th International Symposium on Targeted Anticancer Therapies 2007, held at Amsterdam, The Netherlands on March 8-10, 2007
    24. Thasni K A, Rakesh S Nair, Rojini G, Ratheesh kumar T, Srinivas Gopal, Asoke Banerjj, Priya Srinivas Naphthaquinones – Promising anticancer agents against breast and ovarian cancer treatment. 30th breast cancer symposium, San Antonio, Texas. December 2007.
    25. Rakesh S Nair, Sivakumar K.C., Eswaranpotti Manoj, Ratheesh kumar. T, M.R. Prathapachandra Kurup, Srinivas G and Priya Srinivas. Induced fit DNA recognition in a cisplatin binding groove by carbohydrazone: structural fluctuations investigated through molecular dynamics simulations. Proceedings of International Symposium on Computational Biology, Bioinformatics and Synthetic biology, held at Centre for Bioinformatics, University of Kerala, Thiruvananthapuram, India, January 2008.
    26. Sangeetha S Nampoothiri, Ratheeshkumar T, Rakesh S Nair, Thasni K A, Srinivas G and Priya Srinivas. Combination Therapy Using Taxol, Cisplatin, Doxorubicin with Plumbagin on Bg1 Ovarian Adenocarcinoma Cell Line. 2008 Inflammation, Microenvironment and Cancer (D2) 3/30/2008 to 4/4/2008; Snowbird, UT; USA.
    27. Priya Srinivas, Rakesh S Nair, Prathapachandra Kurup M.R and Mini Kuriakose. Molecular trail for the action of a metal based drug in HPV positive cervical cancer cells. The Seventh Annual AACR International Conference on Frontiers in Cancer Prevention, Washington, DC, U.S.A, 16th to 21st December,2008.
    28. Rakesh Sathish Nair, Thasni K A, Jerald Mahesh Kumar, Asoke Banerji, Srinivas G and Priya Srinivas. Transition of a molecule from Indian indigenous medicine to the arena of molecular cancer research.17th Annual Short Course on Experimental Models of Human Cancer at Jackson laboratory, Bar Harbour, Maine, USA, 22nd to 31st August 2008
    29. In vitro Anticancer activity of alo emodin involves G2/M arrest and inhibition of metastasis in colon cancer cells. Priya Prasanna Sathiadevan, Suboj Babykutty, Vinod Vijayakurup, Priya Srinivas,Gopal Srinivas. International PSE symposioum on Natural products in cancer therapy. Italy, 2008
    30. Srinivas Gopala, M Radhakrishna Pillai, Priya Srinivas. Molecular mechnism of plumbagin action: an update on its antitumor function. International PSE Symposium on Natural Products in Cancer Therapy, 23-26 September 2008, Naples Italy.
    31. Nitric oxide-cGMP-MMP2/9 circuit in colon cancer migration and invasiveness: An in vitro study. Suboj Babykutty, Priya Prasanna Sathiadevan, Vinod Vijayakurup, Padmakrishnan. C. J, Priya Srinivas, Gopal Srinivas. ECCO 15 -ESMO 34 Multidisciplinary Congress, Berlin, 2009.
    32. Rakesh S, J Mahesh Kumar, Jedy Jose, Anil Kumar T V, Chuxia Deng, Priya Srinivas. Quinone as drug targets against homologous recombination deficient tumors, International cancer research Symposium-20-22nd, December 2010.
    33. Priya Srinivas, Veena Somasundaram, Rakesh S, Thasni KA, Premakumari P, Srinivas G. Multifaceted approach with a single drug for BRCA1 defective cancers. Current Medicinal Chemistry, Special Issue, Abstracts- 3rd International Conference on Drug Discovery and Therapy, Dubai, Feb, 2011, p 107.
    34. Veena Somasundaram, Priya Srinivas. A Study of Breast cancer stem cells isolated from BRCA1 mutated cell lines in comparison to those isolated from cell lines with wild type BRCA1' paper presented and won consolation prize at 'The 2nd International Conference on Stem Cells and Cancer (ICSCC-2011) – Proliferation, Differentiation and Apoptosis', Pune, 15th -18th October, 2011.
    35. Priya Srinivas, Rakesh S Nair, Sutapa Singha, Debabrata Mukhopadhyay, Differential sensitivity patterns of a naphthaquinone in cancer: possible mechanisms to BRCA1 and BRCA2 genes. 21st Asia Pacific Cancer Conference, Kuala Lumpur, Malaysia. November 10-12, 2011.
    36. Suboj Babykutty, Priya Prasanna Sathiadevan, Priya Srinivas, S Gopala. Insidious role of nitric oxide in migration / invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. 21st Asia Pacific Cancer Conference, Kuala Lumpur, Malaysia. November 10-12, 2011.
    37. Veena Somasundaram, Sreelatha K H, Reshma R S, Rakesh S and Priya Srinivas. 'Defects in BRCA1-Novel clues to targeting Breast Cancer Stem Cells.' Paper Presented at the 32nd Annual Convention of the Indian Asociation for Cancer Research, University of Delhi (North Campus) from February 13-16, 2013.
    38. Sreelatha KH, Reshma RS, Veena S, Rakesh SN, Thara Somanathan, Jem Prabhakar, and Priya Srinivas. Mammary Cancer Associated Fibroblast (CAF) mediated breast tumor progression, an in vitro study. Poster Presented at the 32nd Annual Convention of the Indian Asociation for Cancer Research, University of Delhi (North Campus) from February 13-16, 2013.
    39. Reshma RS, Sreelatha KH, Veena Somasundaram, Rakesh SN, Priya Srinivas. Castrate Resistant Prostate Cancer and Naphthaquinones. Poster Presented at the 32nd Annual Convention of the Indian Asociation for Cancer Research, University of Delhi (North Campus) from February 13-16, 2013.
    40. S Veena, KH Sreelatha, RS Reshma, SN Rakesh, S Priya. 'Carboplatin and ALDH1+ Breast Cancer Stem Cells: Unseen Facts. Poster Presented at the 11th International Congress on Targeted Anticancer Therapies, Paris, France, March 4-6, 2013. Annals of Oncology 24 (Supplement 1): i30-i32, 2013.
    41. S Priya, RS Reshma, SN Rakesh, KH Sreelatha, S Veena. 'Novel Phytochemical to target BRCA2 Related Prostate Cancer. Poster Presented at the 11th International Congress on Targeted Anticancer Therapies, Paris, France, March 4-6, 2013. Annals of Oncology 24 (Supplement 1): i23-i26, 2013
    42. K. H. Sreelatha, R. S. Reshma, S. Veena, S. N. Rakesh, S. Thara, P. Jem, S. Priya. Influence of Cancer Associated Fibroblast (CAF) on human breast cancer cells in an in vitro co-culture model. Poster Presented at the 11th International Congress on Targeted Anticancer Therapies, Paris, France, March 4-6, 2013. Annals of Oncology 24 (Supplement 1): i30-i32, 2013
    43. Veena Somasundaram, Reshma RS, Sreelatha KH, Revathy, Satheesh Kumar S, Priya Srinivas. 'Inducers of NO and ROS: Implications in Homologous Recombination Defective Breast Cancer Cells'. Poster presented at the Legacy of Nitric Oxide Discovery: Impact on Disease Biology, Rajiv Gandhi Centre for Biotechnology, Kerala, India, November 5-6, 2013
    1. Veena Somasundaram, Sreelatha KH, Reshma RS, Rakesh SN, Priya Srinivas 'Carboplatin and ALDH1+ Breast Cancer Stem Cells: Unseen Facts. Annals of Oncology, Supplement 1, March, 2013, p i30
    2. Sreelatha KH, Reshma RS, Veena Somasundaram, Rakesh SN, Thara Somanthan, Jem Prabhakar, Priya Srinivas. Influence of Cancer Associated Fibroblast (CAF) on human breast cancer cells in an invitro co-culture model. Annals of Oncology 24 Supplement 1, March, 2013, p i30.
    3. Priya Srinivas, Reshma RS, Rakesh S, Sreelatha KH, Veena Somasundaram. Novel phytochemical to target BRCA2 related prostate cancer. Annals of Oncology 24 Supplement 1, March, 2013, p i25.
    4. Priya Srinivas, Veena Somasundaram, Rakesh S, Thasni KA, Premakumari P, Srinivas G. Multifaceted approach with a single drug for BRCA1 defective cancers. Current Medicinal Chemistry, Special Issue, (Abstract), p 107, 2011.
    5. Priya Srinivas, Rakesh S Nair, Prathapachandra Kurup M.R and Mini Kuriakose. Molecular trail for the action of a metal based drug in HPV positive cervical cancer cells. (Abstract), Cancer Prevention Research: Volume 1, Issue 7, Supplement. doi: 10.1158/1940-6207.PREV-08-A71, November 2008.
    6. Thasni K A, Rakesh S Nair, Rojini G, Ratheesh kumar T, Srinivas Gopal, Asoke Banerjj, Priya Srinivas Naphthaquinones – Promising anticancer agents against breast and ovarian cancer treatment. (Abstract) – Breast Cancer Research and Treatment, Vol 106, Supplement 1, December 2007.
    7. Thasni K A, Rojini G, Srinivas G, Asoke Banerji, Priya Srinivas. Molecular mechanism of action of plumbagin in BRCA1 blocked ovarian cancer cell line by suppression subtractive hybridization and micro array. (Abstract) Annals of Oncology, Volume 18, Supplement 4, May 2007.
    8. Priya Srinivas, Thasni K A, Rakesh S Nair, Rojini G, Ratheeshkumar T, Asoke Banerji, Srinivas G. Targeted anticancer therapy for BRCA1 blocked estrogen receptor positive ovarian cancers. (Abstract) Annals of Oncology, Volume 18, Supplement 4, May 2007.
  • Team


    Ratheeshkumar T, PhD (SERB - National Post-doctoral Fellow)

    Pancreatic ductal adenocarcinoma (PDAC) is the most common among pancreatic cancers and is one of the greatest challenges in cancer research because of the late detection and lack of proper treatment strategies. Population based studies indicate that breast cancer susceptibility genes BRCA1, BRCA2 mutation and insulin administration are high risk factors in developing PDAC. Never the less the molecular mechanism behind is largely unknown. My preliminary objective is the in vitro evaluation of the molecular mechanism behind the occurrence of PDAC in BRCA1/BRCA2 mutated patients undertaking insulin administration.

    Ratheesh Kumar T
    Ratheesh Kumar T

    Ratheeshkumar T, PhD (SERB - National Post-doctoral Fellow)

    Pancreatic ductal adenocarcinoma (PDAC) is the most common among pancreatic cancers and is one of the greatest challenges in cancer research because of the late detection and lack of proper treatment strategies. Population based studies indicate that breast cancer susceptibility genes BRCA1, BRCA2 mutation and insulin administration are high risk factors in developing PDAC. Never the less the molecular mechanism behind is largely unknown. My preliminary objective is the in vitro evaluation of the molecular mechanism behind the occurrence of PDAC in BRCA1/BRCA2 mutated patients undertaking insulin administration.

    Sreelatha K H, PhD Student

    Genetic and cell biology studies reveals that the tumor growth is not only determined by the malignant cells but also their immediate tumor stroma. Recently the importance of stromal microenvironment of cancers in their origin, development and invasive nature was implicated in many studies. Influence of tumor microenvironment on BRCA1 defective cancer progression has not been analyzed yet. Therefore my study targets on tumor microenvironment especially Cancer Associated Fibroblasts (CAFs) on cancer cells.

    sreelatha
    sreelatha

    Sreelatha K H, PhD Student

    Genetic and cell biology studies reveals that the tumor growth is not only determined by the malignant cells but also their immediate tumor stroma. Recently the importance of stromal microenvironment of cancers in their origin, development and invasive nature was implicated in many studies. Influence of tumor microenvironment on BRCA1 defective cancer progression has not been analyzed yet. Therefore my study targets on tumor microenvironment especially Cancer Associated Fibroblasts (CAFs) on cancer cells.

    Reshma R S, PhD Student

    Prostate cancer has become the third most common cancer in men accounting for almost 10% of all male cancers. Prostate gland is controlled by steroid hormones and thus BRCA1/2 proteins could be of functional importance since BRCA1 is reported to influence Estrogen receptor/Androgen receptor expression. The main objective of the study is to analyze the effect of plumbagin and related quinones in comparison to standard drugs given to prostate cancer patients in BRCA 1-/+ prostate cancer cell lines.

    reshma
    reshma

    Reshma R S, PhD Student

    Prostate cancer has become the third most common cancer in men accounting for almost 10% of all male cancers. Prostate gland is controlled by steroid hormones and thus BRCA1/2 proteins could be of functional importance since BRCA1 is reported to influence Estrogen receptor/Androgen receptor expression. The main objective of the study is to analyze the effect of plumbagin and related quinones in comparison to standard drugs given to prostate cancer patients in BRCA 1-/+ prostate cancer cell lines.

    Revathy, PhD Student

    Molecular Alterations in Gestational Trophoblastic Diseases

    Gestational trophoblastic diseases comprises of a range of pregnancy related tumors, from pre-malignant to the malignant tumors where β-hCG peaks higher than even the level during pregnancy. The reported incidences of the GTD vary widely, the highest incidence being in South-East Asia especially India and very high in Kerala with 5.1/1000 deliveries. The disease biology being vague, methods to determine the malignant potential being limited and the chances of recurrence of GTDs being high, creates the scenario to unravel the molecular mechanisms behind GTD to find a cure for this disease.

    revathy
    revathy

    Revathy, PhD Student

    Molecular Alterations in Gestational Trophoblastic Diseases

    Gestational trophoblastic diseases comprises of a range of pregnancy related tumors, from pre-malignant to the malignant tumors where ß-hCG peaks higher than even the level during pregnancy. The reported incidences of the GTD vary widely, the highest incidence being in South-East Asia especially India and very high in Kerala with 5.1/1000 deliveries. The disease biology being vague, methods to determine the malignant potential being limited and the chances of recurrence of GTDs being high, creates the scenario to unravel the molecular mechanisms behind GTD to find a cure for this disease.

    Satheesh Kumar S, PhD Student

    Regulation of hormones in breast cancer: An in vitro study

    Hormones play a critical role in breast tissue development but during cancerous condition the hormones are abnormally activated, that lead to the progression of tumor. But the role played by hormones during triple negative condition is clearly unknown. We are studying the cellular effect of hormones particularly hCG and its molecular regulation in triple negative breast cancer

    satheesh
    satheesh

    Satheesh Kumar S, PhD Student

    Regulation of hormones in breast cancer: An in vitro study

    Hormones play a critical role in breast tissue development but during cancerous condition the hormones are abnormally activated, that lead to the progression of tumor. But the role played by hormones during triple negative condition is clearly unknown. We are studying the cellular effect of hormones particularly hCG and its molecular regulation in triple negative breast cancer

    Arathi Rajan, PhD Student

    BRCA1 and BRCA2 are major tumor suppressor proteins, that help in repairing damaged DNA, thus ensuring the stability of the cell's genetic material. The germ-line inactivation of BRCA1 pre-disposes predominantly to the cancers of the breast and ovary. Together, BRCA1 and BRCA2 mutations account for about 5 to 10 percent of all breast cancers and 20 to 25 percent of hereditary breast cancers. My study involves the analysis of the exact role of BRCA1 in DNA damage and repair and the resultant breast cancer - tumorigenesis.

    arathi
    arathi

    Arathi Rajan, PhD Student

    BRCA1 and BRCA2 are major tumor suppressor proteins, that help in repairing damaged DNA, thus ensuring the stability of the cell’s genetic material. The germ-line inactivation of BRCA1 pre-disposes predominantly to the cancers of the breast and ovary. Together, BRCA1 and BRCA2 mutations account for about 5 to 10 percent of all breast cancers and 20 to 25 percent of hereditary breast cancers. My study involves the analysis of the exact role of BRCA1 in DNA damage and repair and the resultant breast cancer - tumorigenesis.

    Geetu Rose Varghese, PhD Student

    A biomarker is a measurable indicator which gives an idea about the risk or progression of a disease from the change in expression levels of a protein/ gene associated with it. Even though, tissue biopsy is the widely used specimen for disease biomarker study, in terms of disease diagnosis and prognosis, a human body fluid appears to be more attractive because body fluid testing provides several key advantages including low invasiveness, minimum cost, and easy sample collection and processing. A number of body fluids have been tested for the presence of biomarker molecules that can be indicative of molecular changes associated with cancer. The study aims to focus on the protein expression signatures in the body fluids of metastatic breast cancer patients.

    Geetu
    Geetu

    Geetu Rose Varghese, PhD Student

    A biomarker is a measurable indicator which gives an idea about the risk or progression of a disease from the change in expression levels of a protein/ gene associated with it. Even though, tissue biopsy is the widely used specimen for disease biomarker study, in terms of disease diagnosis and prognosis, a human body fluid appears to be more attractive because body fluid testing provides several key advantages including low invasiveness, minimum cost, and easy sample collection and processing. A number of body fluids have been tested for the presence of biomarker molecules that can be indicative of molecular changes associated with cancer. The study aims to focus on the protein expression signatures in the body fluids of metastatic breast cancer patients.

    Neetha R L, PhD Student

    The gene product of BRCA1, which is a well-established tumor suppressor gene, functions in a number of cellular pathways that maintain genomic stability including DNA damage-induced cell cycle checkpoint activation, DNA damage repair, protein ubiquitination, chromatin remodeling, as well as transcriptional regulation and apoptosis. BRCA1 related tumorigenesis is mainly caused by the increased DNA damage and decreased genome stability. Although the precise role of BRCA1 in breast tumor prevention remains elusive, it is still not clear that why BRCA1 related patients have higher risk for cancer development mainly in estrogen responsive tissues such as breast and ovary. Hence, the study would focus on the analysis of tumor biology in BRCA1 related cancers.

    Neetha R L
    Neetha R L

    Neetha R L, Junior Research Fellow

    The gene product of BRCA1, which is a well-established tumor suppressor gene, functions in a number of cellular pathways that maintain genomic stability including DNA damage-induced cell cycle checkpoint activation, DNA damage repair, protein ubiquitination, chromatin remodeling, as well as transcriptional regulation and apoptosis. BRCA1 related tumorigenesis is mainly caused by the increased DNA damage and decreased genome stability. Although the precise role of BRCA1 in breast tumor prevention remains elusive, it is still not clear that why BRCA1 related patients have higher risk for cancer development mainly in estrogen responsive tissues such as breast and ovary. Hence, the study would focus on the analysis of tumor biology in BRCA1 related cancers.

    Arya Nagendran,Technical Assistant

    arya
    arya

    Arya Nagendran,Technical Assistant

    Jithin Dev S U, Technical Assistant

    JITHIN
    JITHIN

    Jithin Dev S U, Technical Assistant

  • Alumni


    Thasni K A

    Post Doctoral Fellow
    Genetic Medicine
    Weill Cornell Medical College
    Doha, Qatar

    thasni
    thasni

    Thasni K A

    Post Doctoral Fellow
    Genetic Medicine
    Weill Cornell Medical College
    Doha, Qatar

    Rakesh Sathish Nair

    Post Doctoral Research Associate
    Dep. of Surgery,
    Post Doctoral Research Associate,
    University of Illinois at Chicago,
    School of Medicine,
    840 South Wood Street, Chicago,
    Illinois 60612,

    rakesh
    rakesh

    Rakesh Sathish Nair

    Post Doctoral Research Associate
    Dep. of Surgery,
    Post Doctoral Research Associate,
    University of Illinois at Chicago,
    School of Medicine,
    840 South Wood Street, Chicago,
    Illinois 60612,

    Veena Somasundaram

    Postdoctoral fellow
    Cancer Inflammation Program
    Building 567, Room# 221
    NCI, Frederick, MD-21702

    veena
    veena

    Veena Somasundaram

    Postdoctoral fellow
    Cancer Inflammation Program
    Building 567, Room# 221
    NCI, Frederick, MD-21702